Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-876-8191
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$230,000.00
Profitability
Miscellaneous
Employees61
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences Inc (NASDAQ:GNCA) issued its quarterly earnings results on Thursday, July, 25th. The biotechnology company reported ($0.67) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.65) by $0.02. View Genocea Biosciences' Earnings History.
When is Genocea Biosciences' next earnings date?
What price target have analysts set for GNCA?
3 brokers have issued 12-month price objectives for Genocea Biosciences' shares. Their forecasts range from $32.00 to $32.00. On average, they expect Genocea Biosciences' share price to reach $32.00 in the next twelve months. This suggests a possible upside of 806.5% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.
What is the consensus analysts' recommendation for Genocea Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.
What are Wall Street analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are lowering our price target to $32 from $42 to reflect the recent dilution, and fully diluted share count from the company’s equity raise." (7/25/2019)
- 2. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (7/3/2019)
Has Genocea Biosciences been receiving favorable news coverage?
News stories about GNCA stock have trended negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Genocea Biosciences earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Genocea Biosciences.
Are investors shorting Genocea Biosciences?
Genocea Biosciences saw a drop in short interest in August. As of August 31st, there was short interest totalling 305,300 shares, a drop of 39.2% from the July 31st total of 502,000 shares. Based on an average trading volume of 824,800 shares, the short-interest ratio is currently 0.4 days. Currently, 2.1% of the shares of the company are short sold. View Genocea Biosciences' Current Options Chain.
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include Adverum Biotechnologies (ADVM), Scholar Rock (SRRK), Gritstone Oncology (GRTS), BioCryst Pharmaceuticals (BCRX), CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA), La Jolla Pharmaceutical (LJPC), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), LogicBio Therapeutics (LOGC), PDL BioPharma (PDLI), Sutro Biopharma (STRO), Compugen (CGEN), Adaptimmune Therapeutics (ADAP) and X4 Pharmaceuticals (XFOR).
What other stocks do shareholders of Genocea Biosciences own?
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)
- Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)
- Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)
- Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)
- Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55)
Who are Genocea Biosciences' major shareholders?
Genocea Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (27.63%), Vanguard Group Inc. (2.87%), Vivo Capital LLC (2.40%), Polaris Venture Management Co. V L.L.C. (0.94%), HighTower Advisors LLC (0.65%) and Renaissance Technologies LLC (0.64%). Company insiders that own Genocea Biosciences stock include George Siber, Michael Alfieri, Peter W Sonsini and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.
Which major investors are selling Genocea Biosciences stock?
GNCA stock was sold by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Vivo Capital LLC, Polaris Venture Management Co. V L.L.C., Vanguard Group Inc., Renaissance Technologies LLC, HighTower Advisors LLC, BlackRock Inc. and Northern Trust Corp. View Insider Buying and Selling for Genocea Biosciences.
Which major investors are buying Genocea Biosciences stock?
GNCA stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, Monashee Investment Management LLC, DRW Securities LLC, Wells Fargo & Company MN, D. E. Shaw & Co. Inc., Citadel Advisors LLC, Wedbush Securities Inc. and Cubist Systematic Strategies LLC. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri, Peter W Sonsini and William D Clark. View Insider Buying and Selling for Genocea Biosciences.
How do I buy shares of Genocea Biosciences?
Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of GNCA stock can currently be purchased for approximately $3.53.
How big of a company is Genocea Biosciences?
Genocea Biosciences has a market capitalization of $92.31 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.View Additional Information About Genocea Biosciences.
What is Genocea Biosciences' official website?
How can I contact Genocea Biosciences?
Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]
MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
